Ovarian Cancer — Year in Review Series on Relevant New Datasets and Advances
Oncology Today with Dr Neil Love
00:00
TDXd in recurrent and frontline development
Kathleen summarizes T-DXd efficacy by HER2 IHC, approvals, and the need for more data in lower HER2 expressers.
Play episode from 49:43
Transcript
